source
- Viridian may have edge over Amgen in eye drug showdown, analysts argueThe FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.BioPharma Dive · 1mo ago↗ source
- Health AI caution crosses into confidenceHow people in health tech feel about AI in healthcare has changed drastically from just a year ago. Each year, health tech venture firm Venrock partners Bob Kocher, Bryan Roberts and Siobhan Nolan…Endpoints · 1mo ago↗ source
- These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.